May 1, 1987Canadian Journal of Neurological Sciences / Journal Canadien des Sciences NeurologiquesOpen Access

At 6 months follow-up, treatment with acetazolamide 250 mg once daily resulted in sustained improvement in myotonia without the development of weakness.

View Full Paper

Ask AI

Bookmark

Why the study?

Does acetazolamide improve myotonia without causing weakness in patients with paramyotonia congenita?

Population

1 26-year-old woman with paramyotonia congenita characterized by paradoxical myotonia and increased…

Design

Case_report

Follow-up

6 months

Authors

TBTimothy Benstead PCPeter Camfield DKDavid King

Discussion

Member takes

Overview

May support low-dose acetazolamide in paramyotonia congenita; leaves open confirmation in controlled trials.

Structured PICO

Does acetazolamide improve myotonia without causing weakness in patients with paramyotonia congenita?

Population

1 26-year-old woman with paramyotonia congenita characterized by paradoxical myotonia and increased stiffness and weakness following exposure to cold.

Intervention

Acetazolamide 125 mg orally initially, then 250 mg orally once daily for 6 months.

Outcome

Improvement in myotonia and weakness assessed clinically and by needle electromyography.

Low-dose acetazolamide can effectively treat myotonia in paramyotonia congenita without inducing the severe weakness previously reported with higher doses.

Limitations

Single case report
Cannot conclude superiority over tocainide
Requires double-blind therapeutic trial in a larger number of patients

Cite This Study

Benstead et al. (1987) studied this question.

synapsesocial.com/papers/6a968f812d8f86faeeb2ed6b https://doi.org/10.1017/s0317167100026305

View Full Paper

Ask AI

Bookmark

May 1, 1987Canadian Journal of Neurological Sciences / Journal Canadien des Sciences NeurologiquesOpen Access

At 6 months follow-up, treatment with acetazolamide 250 mg once daily resulted in sustained improvement in myotonia without the development of weakness.

View Full Paper

Ask AI

Bookmark

Why the study?

Does acetazolamide improve myotonia without causing weakness in patients with paramyotonia congenita?

Population

1 26-year-old woman with paramyotonia congenita characterized by paradoxical myotonia and increased…

Design

Case_report

Follow-up

6 months

Authors

TBTimothy Benstead PCPeter Camfield DKDavid King

Discussion

Member takes

Overview

May support low-dose acetazolamide in paramyotonia congenita; leaves open confirmation in controlled trials.

Structured PICO

Does acetazolamide improve myotonia without causing weakness in patients with paramyotonia congenita?

Population

1 26-year-old woman with paramyotonia congenita characterized by paradoxical myotonia and increased stiffness and weakness following exposure to cold.

Intervention

Acetazolamide 125 mg orally initially, then 250 mg orally once daily for 6 months.

Outcome

Improvement in myotonia and weakness assessed clinically and by needle electromyography.

Low-dose acetazolamide can effectively treat myotonia in paramyotonia congenita without inducing the severe weakness previously reported with higher doses.

Limitations

Single case report
Cannot conclude superiority over tocainide
Requires double-blind therapeutic trial in a larger number of patients

Cite This Study

Benstead et al. (1987) studied this question.

synapsesocial.com/papers/6a968f812d8f86faeeb2ed6b https://doi.org/10.1017/s0317167100026305

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark